![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
PRESENTER
Bethany Mooney, CRNP W/PA University of Pennsylvania Philadelphia, PA
Kindly Reply by
August 18, 2020 In the RSVP, please include your Name, Contact Information, Organization, and Specialty.
DATE AND TIME
Tuesday, August 25, 2020 6:00 PM ET
RSVP
To: https://astellas.virtualspeakercast.net/Registration/index/39 Phone: Email:
INDICATION
PADCEV (enfortumab vedotin-ejfv) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.